Malloy Kirk 4

What Happened Kirk Malloy, a director of Rapid Micro Biosystems (RPID), received equity awards on May 21, 2026. The filing shows two awards totaling 58,000 units: 19,300 shares reported as an award (A) at $0.00 and 38,700 reported as a derivative award (A) at $0.00. No cash was paid — these are restricted stock unit (RSU) grants rather than open‑market purchases or sales.

Key Details

• Transaction date: 2026-05-21; Form 4 filed: 2026-05-26 (appears late relative to the usual 2 business‑day Section 16 reporting requirement).
• Awards: 19,300 shares (non‑derivative award) + 38,700 derivative RSUs = 58,000 total units; price reported $0.00.
• Vesting (Footnote F1): RSUs vest in full on the earlier of (i) the first anniversary of the grant or (ii) the day before the next annual meeting, subject to continuous service.
• Footnote F2: Some shares are held in a family trust in which the reporting person shares investment power/beneficial interest.
• Footnote F3 (included in filing): describes an option vesting schedule (noted in filing but not tied to a reported option exercise here).
• Shares owned after the transaction are not specified in the provided filing details.

Context These transactions are awards (code A), not purchases or sales; the derivative designation means the 38,700 units represent rights to receive shares upon vesting rather than immediately issued common stock. Awards and grants are common for directors as compensation and do not by themselves indicate buying or selling sentiment. The late filing may be relevant for compliance monitoring but does not change the nature of the grant.